SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-057788
Filing Date
2018-11-08
Accepted
2018-11-08 17:34:13
Documents
2
Period of Report
2018-11-06

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2183
2 POA DOCUMENT poa.txt EX-24.3_816317 2497
  Complete submission text file 0001209191-18-057788.txt   6145
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Issuer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O DENALI THERAPEUTICS INC. 151 OYSTER POINT BLVD., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
Cook Jennifer E. (Reporting) CIK: 0001754371 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38311 | Film No.: 181170812